Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

Overview of attention for article published in BMC Medicine, December 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 10,779 followers.

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2 ... - BMC Medicine https://t.co/mSOSSmLC2A

PHEDRA Trial. #bcsm Disappointing trial design🫤 https://t.co/JGFyDMlKUI

Collaborative #RCT lead by researchers @FudanUniv provides new options for HER2-positive early or locally advanced #breastcancer. https://t.co/hIGgmJAzf8 https://t.co/dOJj0mGfYc

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2 ... - BMC Medicine https://t.co/mSOSSmLC2A

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.